CSIMarket Company Name, Ticker, Industry, else..
 
Black Diamond Therapeutics Inc   (NASDAQ: BDTX)
 
Price: $2.0400 $-0.06 -2.857%
Day's High: $2.109999895095825 Week Perf: -10.13 %
Day's Low: $ 2.02 30 Day Perf: 17.58 %
Volume (M): 759,094 52 Wk High: $ 4.94
Volume (M$): $ 0 52 Wk Avg: $2.69
Open: $2.10 52 Wk Low: $1.60



 Market Capitalization (Millions $) 117
 Shares Outstanding (Millions) 57
 Employees 21
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) -68
 Capital Exp. (TTM) (Millions $) 0

Business Description


Black Diamond Therapeutics Inc is a biotechnology company that focuses on developing targeted therapies for cancer treatment. They utilize their proprietary platform called Mutation-Allostery-Pharmacology (MAP) to identify and target specific genetic mutations that drive cancer growth. By addressing these mutations, Black Diamond aims to create novel and effective therapies that improve patient outcomes. They are dedicated to advancing precision medicine and tackling the most challenging oncology indications.


   Company Address: 245 First Street, 18th Floor Cambridge 2142 MA
   Company Phone Number: 252-0848   Stock Exchange / Ticker: NASDAQ BDTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BCRX        0.92% 
BIIB   -2.14%    
GILD        0.77% 
IMCR   -1.44%    
IPSC   -6.45%    
RGNX        4.6% 
• View Complete Report
   



Partnership

Servier and Black Diamond Therapeutics Forge Global Alliance for BDTX-4933 A New Hope for Patients with RAF/RAS-Mutan...

Published Wed, Mar 19 2025 11:51 AM UTC

SURESNES, France and CAMBRIDGE, Mass. March 19, 2025 Servier, an independent global pharmaceutical group guided by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company focusing on MasterKey therapies targeting specific oncogenic mutations, have announced a strategic worldwide licensing agreement for BDTX-4933. Thi...
Announcement

Navigating the Future of Oncology Black Diamond Therapeutics’ Third Quarter Insights,

Published Tue, Nov 5 2024 1:00 PM UTC

Advancing Oncogenic Therapeutics: Black Diamond Therapeutics Reports Promising Financial and Corporate DevelopmentsIn an era where precision medicine is not merely an ambition but an urgent necessity, Black Diamond Therapeutics, Inc. has emerged as a beacon of hope in the oncology landscape. Headquartered in the vibrant city of Cambridge, Massachusetts, this clinical-stage ...
Clinical Study

Black Diamond Therapeutics A New Era in Oncogenic Mutation Combat with BDTX-1535,

Published Mon, Sep 23 2024 11:00 AM UTC

In a pivotal move in the oncology sector, Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) recently announced compelling results in their ongoing clinical trials for BDTX-1535, a new hope in the treatment of recurrent EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM). These results were shared in advance of their presentations at the 2024 American Society ...
Clinical Study

A New Era in EGFRm NSCLC Treatment Black Diamond Therapeutics Initial Phase 2 BDTX-1535 Results Shine,

Published Sun, Sep 22 2024 2:00 PM UTC

Black Diamond Therapeutics Announces Initial Phase 2 BDTX-1535 Results in Recurrent EGFRm NSCLC Patients: A Promising Step Forward Black Diamond Therapeutics, a leading precision oncology medicine company, has announced an upcoming webcast presentation of initial Phase 2 data for BDTX-1535, a novel agent targeting EGFR mutations in patients with recurrent non-small cell lung...
Clinical Study

Recurrent glioblastoma multiforme (GBM), a highly aggressive m...

Published Sat, Jun 1 2024 2:00 PM UTC

A Promising Step Forward in Glioblastoma Treatment: BDTX-1535 Shows Encouraging Clinical Data Recurrent glioblastoma multiforme (GBM), a highly aggressive malignant brain tumor, remains one of the most challenging cancers to treat due to its resistance to conventional therapies and poor prognosis. In the ongoing pursuit of novel therapeutic strategies, Black Diamond Therap...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 0.01
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1.12
PEG (TTM) -

Financial Strength Current
Quick Ratio 8.14
Working Capital Ratio 8.46
Leverage Ratio (MRQ) 0.27
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 387.42 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 2.07 $
Book Value 1.82 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,057,667
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.